Arrowhead’s Focus On Plozasiran Intensifies Competition With Ionis

Drug May Reach Market In 2025, After Olezarsen

 
• By Mandy Jackson

Arrowhead’s in-house, late-stage cardiovascular disease programs will center on triglyceride-lowering plozasiran while it seeks a partner to fund Phase III for cholesterol-reducing zodasiran.

London, UK. 3rd January 2024. Horse racing events in the UK.
Targeting APOC3 is a two-horse race in hypertriglyceridemia • Source: Shutterstock

More from Cardiovascular

More from Therapy Areas